Crystal structures of inhibitor complexes of human T-Cell leukemia virus (HTLV-1) protease

Journal of Molecular Biology

Volumn 401, Issue 4, 2010, Pages 626-641

  Satoh, Tadashi ^a   Li, Mi ^a,b   Nguyen, Jeffrey Tri ^c   Kiso, Yoshiaki ^c   Gustchina, Alla ^a   Wlodawer, Alexander ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

^c KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Drug design; Inhibitors; Leukemia; Protease; Retrovirus

Indexed keywords

KNI 10220; KNI 10296C; KNI 10516; KNI 10562; KNI 10673; KNI 10681; KNI 10683; KNI 10729; KNI 1595B; PROTEINASE; PROTEINASE INHIBITOR; STATINE; UNCLASSIFIED DRUG;

ARTICLE; CRYSTAL STRUCTURE; CRYSTALLIZATION; ENZYME INHIBITOR COMPLEX; ENZYME PURIFICATION; ENZYME STRUCTURE; HUMAN T CELL LEUKEMIA VIRUS 1; HYDROGEN BOND; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN T-LYMPHOTROPIC VIRUS 1;

EID: 77955334997     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2010.06.052     Document Type: Article

References (33)

1. Franchini G., Fukumoto R., Fullen J.R. T-cell control by human T-cell leukemia/lymphoma virus type 1. Int. J. Hematol. 2003, 78:280-296.
2. Uchiyama T. Human T cell leukemia virus type I (HTLV-I) and human diseases. Annu. Rev. Immunol. 1997, 15:15-37.
3. Ishikawa T. Current status of therapeutic approaches to adult T-cell leukemia. Intl. J. Hematol. 2003, 78:304-311.
4. Nasr R., El Sabban M.E., Karam J.A., Dbaibo G., Kfoury Y., Arnulf B., et al. Efficacy and mechanism of action of the proteasome inhibitor PS-341 in T-cell lymphomas and HTLV-I associated adult T-cell leukemia/lymphoma. Oncogene 2005, 24:419-430.
5. Kannagi M., Harashima N., Kurihara K., Utsunomiya A., Tanosaki R., Masuda M. Adult T-cell leukemia: future prophylaxis and immunotherapy. Expert Rev. Anticancer Ther. 2004, 4:369-376.
6. Wlodawer A. Rational approach to AIDS drug design through structural biology. Annu. Rev. Med. 2002, 53:595-614.
7. Gustchina A., Jaskolski M., Wlodawer A. Lessons learned fighting HIV can be applied to anti-cancer drug design. Cell Cycle 2006, 5:463-464.
8. Tozser J., Weber I.T. The protease of human T-cell leukemia virus type-1 is a potential therapeutic target. Curr. Pharm. Des. 2007, 13:1285-1294.
9. Shuker S.B., Mariani V.L., Herger B.E., Dennison K.J. Understanding HTLV-I protease. Chem. Biol. 2003, 10:373-380.
10. Louis J.M., Oroszlan S., Tozser J. Stabilization from autoproteolysis and kinetic characterization of the human T-cell leukemia virus type 1 proteinase. J. Biol. Chem. 1999, 274:6660-6666.
11. Tozser J., Zahuczky G., Bagossi P., Louis J.M., Copeland T.D., Oroszlan S., et al. Comparison of the substrate specificity of the human T-cell leukemia virus and human immunodeficiency virus proteinases. Eur. J. Biochem. 2000, 267:6287-6295.
12. Vondrasek J., Wlodawer A. HIVdb: a database of the structures of human immunodeficiency virus protease. Proteins 2002, 49:429-431.
13. Li M., Laco G.S., Jaskólski M., Rozycki J., Alexandratos J., Wlodawer A., Gustchina A. Crystal structure of human T-cell leukemia virus protease, a novel target for anti-cancer drug design. Proc. Natl Acad. Sci. USA 2005, 102:18322-18337.
14. Abdel-Rahman H.M., Kimura T., Hidaka K., Kiso A., Nezami A., Freire E., et al. Design of inhibitors against HIV, HTLV-I, and Plasmodium falciparum aspartic proteases. Biol. Chem. 2004, 385:1035-1039.
15. Maegawa H., Kimura T., Arii Y., Matsui Y., Kasai S., Hayashi Y., Kiso Y. Identification of peptidomimetic HTLV-I protease inhibitors containing hydroxymethylcarbonyl (HMC) isostere as the transition-state mimic. Bioorg. Med. Chem. Lett. 2004, 14:5925-5929.
16. Bagossi P., Kadas J., Miklossy G., Boross P., Weber I.T., Tozser J. Development of a microtiter plate fluorescent assay for inhibition studies on the HTLV-1 and HIV-1 proteinases. J. Virol. Methods 2004, 119:87-93.
17. Wlodawer A., Vondrasek J. Inhibitors of HIV-1 protease: a major success of structure-assisted drug design. Annu. Rev. Biophys. Biomol. Struct. 1998, 27:249-284.
18. Zhang M., Nguyen J.T., Kumada H.O., Kimura T., Cheng M., Hayashi Y., Kiso Y. Locking the two ends of tetrapeptidic HTLV-I protease inhibitors inside the enzyme. Bioorg. Med. Chem. 2008, 16:6880-6890.
19. Jaskolski M., Li M., Laco G., Gustchina A., Wlodawer A. Molecular replacement with pseudosymmetry and model dissimilarity: a case study. Acta Crystallogr., Sect. D: Biol. Crystallogr. 2006, 62:208-215.
20. Zhang M., Nguyen J.T., Kumada H.O., Kimura T., Cheng M., Hayashi Y., Kiso Y. Synthesis and activity of tetrapeptidic HTLV-I protease inhibitors possessing different P3-cap moieties. Bioorg. Med. Chem. 2008, 16:5795-5802.
21. Nguyen J.T., Zhang M., Kumada H.O., Itami A., Nishiyama K., Kimura T., et al. Truncation and non-natural amino acid substitution studies on HTLV-I protease hexapeptidic inhibitors. Bioorg. Med. Chem. Lett. 2008, 18:366-370.
22. Brünger A.T. The free R value: a novel statistical quantity for assessing the accuracy of crystal structures. Nature 1992, 355:472-474.
23. Clemente J.C., Govindasamy L., Madabushi A., Fisher S.Z., Moose R.E., Yowell C.A., et al. Structure of the aspartic protease plasmepsin 4 from the malarial parasite Plasmodium malariae bound to an allophenylnorstatine-based inhibitor. Acta Crystallogr., Sect. D: Biol. Crystallogr. 2006, 62:246-252.
24. Krissinel E., Henrick K. Secondary-structure matching (SSM), a new tool for fast protein structure alignment in three dimensions. Acta Crystallogr., Sect. D: Biol. Crystallogr. 2004, 60:2256-2268.
25. Wlodawer A., Erickson J.W. Structure-based inhibitors of HIV-1 protease. Annu. Rev. Biochem. 1993, 62:543-585.
26. Dauter Z., Botos I., LaRonde-LeBlanc N., Wlodawer A. Pathological crystallography-case studies of several unusual macromolecular crystals. Acta Crystallogr., Sect. D: Biol. Crystallogr. 2005, 61:967-975.
27. Otwinowski Z., Minor W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 1997, 276:307-326.
28. Vagin A., Teplyakov A. MOLREP: an automated program for molecular replacement. J. Appl. Crystallogr. 1997, 30:1022-1025.
29. Adams P.D., Grosse-Kunstleve R.W., Hung L.W., Ioerger T.R., McCoy A.J., Moriarty N.W., et al. PHENIX: building new software for automated crystallographic structure determination. Acta Crystallogr., Sect. D: Biol. Crystallogr. 2002, 58:1948-1954.
30. Murshudov G.N., Vagin A.A., Dodson E.J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr., Sect. D: Biol. Crystallogr. 1997, 53:240-255.
31. Emsley P., Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr., Sect. D: Biol. Crystallogr. 2004, 60:2126-2132.
32. Laskowski R.A., MacArthur M.W., Moss D.S., Thornton J.M. PROCHECK: program to check the stereochemical quality of protein structures. J. Appl. Crystallogr. 1993, 26:283-291.
33. DeLano W.L. The PyMOL Molecular Graphics System 2002, DeLano Scientific, San Carlos, CA.